Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study.
extensive surgery
ovarian cancer
quality of life
ultraradical surgery
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
22
10
2021
received:
20
05
2021
accepted:
01
12
2021
pubmed:
6
12
2021
medline:
20
5
2022
entrez:
5
12
2021
Statut:
ppublish
Résumé
To investigate quality of life (QoL) and association with surgical complexity and disease burden after surgical resection for advanced ovarian cancer in centres with variation in surgical approach. Prospective multicentre observational study. Gynaecological cancer surgery centres in the UK, Kolkata, India, and Melbourne, Australia. Patients undergoing surgical resection (with low, intermediate or high surgical complexity score, SCS) for late-stage ovarian cancer. Primary: change in global score on the European Organisation for Research and Treatment of Cancer (EORTC) core quality-of-life questionnaire (QLQ-C30). Secondary: EORTC ovarian cancer module (OV28), progression-free survival. Patients' preoperative disease burden and SCS varied between centres, confirming differences in surgical ethos. QoL response rates were 90% up to 18 months. Mean change from the pre-surgical baseline in the EORTC QLQ-C30 was 3.4 (SD 1.8, n = 88) in the low, 4.0 (SD 2.1, n = 55) in the intermediate and 4.3 (SD 2.1, n = 52) in the high-SCS group after 6 weeks (p = 0.048), and 4.3 (SD 2.1, n = 51), 5.1 (SD 2.2, n = 41) and 5.1 (SD 2.2, n = 35), respectively, after 12 months (p = 0.133). In a repeated-measures model, there were no clinically or statistically meaningful differences in EORTC QLQ-C30 global scores between the three SCS groups (p = 0.840), but there was a small statistically significant improvement in all groups over time (p < 0.001). The high-SCS group experienced small to moderate decreases in physical (p = 0.004), role (p = 0.016) and emotional (p = 0.001) function at 6 weeks post-surgery, which resolved by 6-12 months. The global QoL of patients undergoing low-, intermediate- and high-SCS surgery improved at 12 months after surgery and was no worse in patients undergoing extensive surgery. Compared with surgery of lower complexity, extensive surgery does not result in poorer quality of life in patients with advanced ovarian cancer.
Identifiants
pubmed: 34865316
doi: 10.1111/1471-0528.17041
pmc: PMC9306902
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1122-1132Subventions
Organisme : National Institute of Health and Care Excellence
Organisme : Australian Society of Gynaecologic Oncologists Inc
Organisme : Department of Science Technology, India - UKIERI
Organisme : Jiv Daya Foundation
Informations de copyright
© 2021 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Références
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565
pubmed: 21833960
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979
Gynecol Oncol. 2007 Oct;107(1):99-106
pubmed: 17602726
Gynecol Oncol. 1998 May;69(2):103-8
pubmed: 9600815
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Gynecol Oncol. 2002 Aug;86(2):163-70
pubmed: 12144823
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Surg Oncol. 2019 Aug;45(8):1425-1431
pubmed: 31027945
Obstet Gynecol. 2006 Jan;107(1):77-85
pubmed: 16394043
Psychooncology. 1999 May-Jun;8(3):260-3
pubmed: 10390738
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Cochrane Database Syst Rev. 2011 Apr 13;(4):CD007697
pubmed: 21491400
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Zentralbl Gynakol. 2003 Mar-Apr;125(3-4):129-35
pubmed: 12961105
J Surg Oncol. 2009 Jun 1;99(7):424-7
pubmed: 19365809
Gynecol Oncol. 2009 Jul;114(1):26-31
pubmed: 19395008
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Gynecol Oncol. 2013 Nov;131(2):437-44
pubmed: 23994107
Ann Surg Oncol. 2019 Sep;26(9):2943-2951
pubmed: 31243666
J Med Internet Res. 2013 Oct 25;15(10):e230
pubmed: 24161667
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Lancet. 2019 Dec 7;394(10214):2084-2095
pubmed: 31791688
Gynecol Oncol. 2020 Oct;159(1):58-65
pubmed: 32712154
J Clin Oncol. 2015 Mar 10;33(8):937-43
pubmed: 25667285
Z Psychosom Med Psychother. 2006;52(3):274-88
pubmed: 17156600
Gynecol Oncol. 2006 Dec;103(3):1083-90
pubmed: 16890277
Gynecol Oncol. 2010 Oct;119(1):38-42
pubmed: 20609464
Gynecol Oncol. 2015 Aug;138(2):246-51
pubmed: 26037900
Eur J Surg Oncol. 2018 Jun;44(6):760-765
pubmed: 29426779
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
BJOG. 2022 Jun;129(7):1122-1132
pubmed: 34865316
Int J Gynecol Cancer. 2019 Oct;29(8):1285-1291
pubmed: 31273066
Int J Gynecol Cancer. 2015 Nov;25(9):1599-607
pubmed: 26397157
Gynecol Oncol. 2017 Jul;146(1):94-100
pubmed: 28411948
Am J Obstet Gynecol. 2010 Feb;202(2):178.e1-178.e10
pubmed: 20113693
Int J Gynecol Cancer. 2011 May;21(4):750-5
pubmed: 21543936
Int J Gynecol Cancer. 2013 Mar;23(3):442-7
pubmed: 23429485